ArticleESC heart failure2025
Comparison of incidence, prevalence and death of aortic stenosis and aortic insufficiency in a nationwide Korean study.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of incidence, prevalence and death of aortic stenosis and aortic insufficiency in a nationwide Korean study.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsFew studies have examined the incidence, prevalence, survival rate and death risk for non-rheumatic and rheumatic aortic stenosis (AS; RAS), aortic insufficiency (AR; RAR) and aortic stenosis with insufficiency (ASAR; RASAR). This study aims to identify the epidemiology of AS, AR, ASAR, RAS, RAR and RASAR. METHODS AND
resultsData were collected from newly diagnosed non-rheumatic and rheumatic aortic valve disorders (AVD, ICD-10: I35 and I06, n = 101 895, female: male = 6:4) including AS, AR, ASAR, RAS, RAR and RASAR, excluding congenital heart disease. The data were sourced from the National Health Insurance Service in Korea from 2006 through 2017. Among all AVD, AR had the highest distribution. More than 70% of AVD patients were age ≥ 60 years. The age-standardized incidence of non-rheumatic AVD remained stable over the decade while the age-standardized prevalence increased. Conversely, both the incidence and prevalence of rheumatic AVD decreased. The 10 year survival rates (SR) of AS (49.2%), ASAR (50.2%) and RAS (51.4%) were lower than those for AR (64.5%) and RAR (69.2%). The adjusted hazard ratio for AVD was higher in individuals who were older, male, had a lower income level, diabetes mellitus, myocardial infarction, heart failure, atrial fibrillation, stroke, chronic kidney disease or malignant neoplasms.
conclusionsOver 70% of AVD patients were age ≥ 60 years. The 10 year SR of AS, ASAR and RAS exhibited similar patterns, all of which were lower than the SR for other AVD. AVD portends a worse prognosis in older individuals, males, those with lower income levels and those with comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.